SCHEDULE: State Street Discloses 5.4% Stake in Sarepta Therapeutics

State Street Corporation has reported a 5.4% beneficial ownership stake in Sarepta Therapeutics Inc. common stock as of September 30, 2025.

Summary

• State Street Corporation, a Massachusetts-based entity, is the reporting person for this Schedule 13G filing.
• The filing pertains to the common stock of Sarepta Therapeutics Inc., with CUSIP Number 803607100.
• State Street Corporation beneficially owns an aggregate of 5,304,907 shares, which represents 5.4% of the class.
• The reporting person holds shared voting power over 5,055,825 shares and shared dispositive power over 5,304,907 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Sarepta Therapeutics Inc.
• Subsidiaries identified as acquiring the security include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant institutional stake, which is generally seen as a vote of confidence, but it contains no operational or financial news about the issuer.

Positives

• State Street Corporation's acquisition of shares is stated to be in the ordinary course of business, indicating a passive investment rather than an attempt to influence control.
• The filing confirms a significant institutional investor's position in Sarepta Therapeutics, potentially signaling confidence in the company's long-term prospects.

Future Outlook

No forward-looking statements or guidance from Sarepta Therapeutics are provided in this filing, as it is a disclosure of beneficial ownership by State Street Corporation.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation)

Industry Context

This filing indicates a significant institutional investment in Sarepta Therapeutics, a biotechnology company. Such disclosures are common for large asset managers like State Street, reflecting their portfolio allocations across various industries, including pharmaceuticals and biotech. It doesn't provide specific industry trends but confirms continued institutional interest in the sector.

Comparison to Industry Standards

• State Street Corporation, as a major institutional investor and parent holding company, routinely files Schedule 13G for its beneficial ownership exceeding 5% in public companies. This is standard practice for large asset managers like BlackRock, Vanguard, and Fidelity, which manage vast portfolios on behalf of clients.
• The 5.4% stake in Sarepta Therapeutics is a typical passive investment size for such institutions, indicating a portfolio allocation rather than an activist position. For example, similar filings often show comparable percentage holdings in other biotech firms like Biogen or Vertex Pharmaceuticals by large institutional investors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Management: Awareness of a large passive institutional holder.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure by State Street Corporation of its passive beneficial ownership in Sarepta Therapeutics. It indicates a significant institutional stake but provides no new operational, financial, or strategic information about Sarepta Therapeutics itself that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on prior analysis of Sarepta's fundamentals and market conditions, as this filing does not introduce new factors for buying or selling.

Keywords

Sarepta Therapeutics, State Street Corporation, Common Stock, Institutional Ownership, SEC Filing, Schedule 13G, Beneficial Ownership, SRPT